Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

 

 

Webcasts

11-12-2019

Management Call to Discuss Positive Topline Pivotal Year 1 CARDINAL Data

Webcast: click here

Press (11-11-19): 
Reata Announces Positive Topline Year One Results From Pivotal Phase 3 Cardinal Study of Bardoxolone Methyl in Patients With Alport Syndrome

Press (11-12-19): 
Reata Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial Results and an Update on Development Programs

Teleconference Information

Date: Tuesday, November 12, 2019
Time: 08:00 am ET
Audience Dial-in (toll-free): (844) 348-3946
Audience Dial-in (international): (213) 358-0892
Access Code: 4159656

 PDF

10-15-2019

Reata Management Call to Discuss Positive Topline Pivotal MOXIe Data

Webcast: click here

Press (10-14-19): 
Reata Announces Positive Topline Results from the MOXIe Registrational Trial of Omaveloxolone in Patients with Friedreich’s Ataxia

Teleconference Information

Date: Tuesday, October 15, 2019
Time: 08:00 am ET
Audience Dial-in (toll-free): (844) 348-3946
Audience Dial-in (international): (213) 358-0892
Access Code: 8653916

Read more
 MP3
 PDF

08-08-2019

Reata Pharmaceuticals Second Quarter Financial Results and Update on Development Programs

Webcast: click here

Press (08-01-2019): 
Reata Pharmaceuticals, Inc. Announces Second Quarter and to Provide Update on Development Programs on August 8, 2019

Press (08-08-2019): 
Reata Pharmaceuticals, Inc. Announces Second Quarter 2019 Financial Results and an Update on Development Programs

Teleconference Information

Date: Thursday, August 08, 2019
Time: 08:00 am ET
Audience Dial-in (toll-free): (844) 348-3946
Audience Dial-in (international): (213) 358-0892
Access Code: 7587139

Read more
 MP3
 PDF

Events and Presentations

10-2019

Corporate Presentation

 PDF

10-18-2019

CNBC Interviews Reata CEO Warren Huff

Video Thumbnail
Reata CEO on positive trial results for drug to treat Friedreich's ataxia

06-14-2019

2019 ERA-EDTA Posters & Presentation

Poster: B. Knebelmann, M.D., Ph.D., Professor of Nephrology, Hôpital Necker, Paris, France presented Baseline Characteristics of the “CARDINAL” Trial: A Phase 3 Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome

Poster: P. Pergola, M.D., Ph.D., Renal Associates, San Antonio, TX, presented Safety and Efficacy of Bardoxolone Methyl in Patients with Rare Chronic Kidney Diseases

Poster: P. Pergola, M.D., Ph.D., Renal Associates, San Antonio, TX, presented Safety and Efficacy of Bardoxolone Methyl in Patients with Focal Segmental Glomerulosclerosis

Presentation: C. Wigley, VP of Research, Reata Pharmaceuticals, presented The Nrf2 Activator Bardoxolone Methyl Inhibits Cyst Formation, Reduces Inflammation, and Improves Mitochondrial Function in Cellular Models of Polycystic Kidney Disease

Read more
 PDF
 PDF

04-16-2019

Muscular Dystrophy Association 2019 Poster

Poster: S.H. Subramony, M.D., Professor of Neurology, University of Florida, Gainesville, FL, presented Baseline Characteristics in Part 2 of “MOXIe” Trial: A Study of the Efficacy and Safety of Omaveloxolone in Patients with Friedreich’s Ataxia.

 PDF